Barcoded Theranostic Nanoparticles for Single-Cell Drug Prescreening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for predicting the therapeutic response of patients to cancer treatment are inadequate, as they fail to account for the heterogeneous tumor microenvironment and are time-consuming, leading to ineffective treatments for many patients.
Innovation Solution
A composition comprising theranostic carriers, such as nanoparticles, that deliver a single-cell therapeutically effective amount of therapeutic agents with unique barcodes, allowing simultaneous screening of multiple agents at single-cell resolution to predict patient-specific potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ex vivo and in vitro assays are used to prescreen multiple drugs for anticancer activity, then the ability to predict patient-specific therapeutic response is improved, but the time required for screening increases to 7-12 months
Solution Approach 1:
The patent segments the tumor tissue into individual cells or small clusters, and segments the drug screening into parallel micro-reactions. Each well in the microplate array contains isolated tumor cells exposed to specific drugs, enabling simultaneous screening of multiple drugs across many cells in parallel rather than sequentially, reducing screening time from months to days while maintaining prediction accuracy
Solution Approach 2:
The patent transitions from traditional 2D cell culture to 3D tissue microarrays embedded in agarose blocks. This dimensional change allows preservation of tumor architecture and cell-cell interactions while enabling high-throughput screening. The 3D structure maintains biological realism for accurate prediction, while the array format enables parallel processing of multiple drug candidates
2Productivity
If cell culture approaches are used for drug screening, then the process is simplified and faster, but the predictive accuracy decreases due to lacking heterogeneous tumor microenvironment
Solution Approach 1:
The patent performs preliminary actions by embedding tumor cells in agarose blocks and creating tissue microarrays before drug screening begins. This pre-organization preserves the heterogeneous tumor microenvironment and cell-cell interactions in advance, allowing subsequent high-speed parallel screening to proceed without compromising biological realism. The structural preparation enables both speed and accuracy simultaneously
Data Source
AI summary
A theranostic composition and method for determining the cell-specific potency of drugs is provided. Further, compositions and methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.